Cat. No.: HY-N1408

trans-Trimethoxyresveratrol

(Synonyms: trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene)

고객리뷰

Based on 1 Customer Validation

Trans-Trimethoxyresveratrol (trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene) is an orally active natural derivative of Resveratrol (HY-16561). Trans-Trimethoxyresveratrol has an enhanced anticancer profile compared to Resveratrol, exhibiting higher potency than resveratrol, with improved cancer cell proliferation inhibition, induction of cell cycle arrest, decreased metastasis, and increased apoptosis. Trans-Trimethoxyresveratrol causes microtubule disassembling and tubulin depolymerization and exerts anti-angiogenic effects through VEGFR2. Trans-Trimethoxyresveratrol can be used for the studies of anti-angiogenic and anti-cancer (such as non-small cell lung cancer and osteosarcoma).

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.35%
CAS No.: 22255-22-7
화학식: C₁₇H₁₈O₃
분자량:270.32

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

trans-Trimethoxyresveratrol Chemical Structure

CAS No.: 22255-22-7

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target^[2]

Caspase 3

VEGFR2

All VEGFR Isoforms :

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	ED₅₀	7.5 μM Compound: 7i	Compound was evaluated for cytotoxicity against human A-549 non-small cell lung cancer cell line. Compound was evaluated for cytotoxicity against human A-549 non-small cell lung cancer cell line.	[PMID: 1613753]
BT-549	IC₅₀	15.6 μM Compound: 3	Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
BXPC-3	GI₅₀	0.35 μg/mL Compound: 1b	Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
BXPC-3	GI₅₀	0.35 μg/mL Compound: 4b	In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line. In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line.	[PMID: 12036362]
Caco-2	IC₅₀	11.95 μM Compound: 9	Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
DU-145	GI₅₀	1.5 μg/mL Compound: 1b	Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
DU-145	GI₅₀	1.5 μg/mL Compound: 4b	In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line. In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line.	[PMID: 12036362]
HCT-116	IC₅₀	1.1 μM Compound: TMS; 66	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition Anticancer activity against human HCT-116 cells assessed as cell growth inhibition	[PMID: 32485531]
HCT-116	IC₅₀	5.7 μM Compound: 8E	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 21215623]
HEK293	EC₅₀	1.7 μM Compound: 11	Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level	[PMID: 26750258]
HEK293	IC₅₀	>10 μM Compound: 11	Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level	[PMID: 26750258]
HEK293	IC₅₀	28.3 μM Compound: 5H6	Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 18487053]
HEK293	IC₅₀	3 μM Compound: 11	Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level	[PMID: 26750258]
HeLa	IC₅₀	13.3 μM Compound: 3	Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
HepG2	IC₅₀	>100 μM Compound: TMS; 66	Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
HL-60	IC₅₀	2.5 μM Compound: 3c	Antiproliferative activity against human HL60 cell line Antiproliferative activity against human HL60 cell line	[PMID: 16686543]
HL-60	IC₅₀	2.5 μM Compound: 5b	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 16580204]
HT-29	ED₅₀	6.9 μM Compound: 7i	Cytotoxicity against human HT-29 colon cell line. Cytotoxicity against human HT-29 colon cell line.	[PMID: 1613753]
HT-29	IC₅₀	14 μM Compound: TMS; 66	Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
HT-29	IC₅₀	16 μM Compound: 4	Cytotoxicity against human HT-29 cells incubated for 24 hrs by MTT assay Cytotoxicity against human HT-29 cells incubated for 24 hrs by MTT assay	[PMID: 36463729]
HT-29	IC₅₀	16.1 μM Compound: 9	Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
IMR-90	IC₅₀	2.1 μM Compound: 8E	Cytotoxicity against human IMR90 cells after 24 hrs by MTT assay Cytotoxicity against human IMR90 cells after 24 hrs by MTT assay	[PMID: 21215623]
Ishikawa	IC₅₀	12.6 μM Compound: TMS; 66	Anti-tumor activity against human ishikawa cells assessed as anti-estrogenic potential Anti-tumor activity against human ishikawa cells assessed as anti-estrogenic potential	[PMID: 32485531]
K562	IC₅₀	10 μM Compound: 3c	Antiproliferative activity against human K562 cell line expressing Bcr-Abl Antiproliferative activity against human K562 cell line expressing Bcr-Abl	[PMID: 16686543]
K562	IC₅₀	6.39 μM Compound: TMRV	Cytotoxicity against Homo sapiens (human) K562 cells assessed as growth inhibition after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0159-y
KB	IC₅₀	10.3 μM Compound: 2	Cytotoxicity against human KB cells after 48 hrs Cytotoxicity against human KB cells after 48 hrs	[PMID: 17000031]
KB	IC₅₀	17.7 μM Compound: 3	Cytotoxicity against human KB cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human KB cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
LLC-PK1	IC₅₀	20 μM Compound: 3	Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
MCF7	ED₅₀	9.7 μM Compound: 7i	Cytotoxicity against human MCF-7 breast cancer cell line. Cytotoxicity against human MCF-7 breast cancer cell line.	[PMID: 1613753]
MCF7	IC₅₀	1.1 μM Compound: 8E	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 21215623]
MCF7	IC₅₀	8.41 μM Compound: TMRV	Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0159-y
MDA-MB-231	IC₅₀	1.2 μM Compound: 3	Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells	[PMID: 16250636]
MDR	IC₅₀	8 μM Compound: 3c	Antiproliferative activity against MDR human HL60R cell line Antiproliferative activity against MDR human HL60R cell line	[PMID: 16686543]
MIA PaCa-2	IC₅₀	35 μM Compound: 4	Cytotoxicity against human MIA PaCa-2 cells incubated for 24 hrs by MTT assay Cytotoxicity against human MIA PaCa-2 cells incubated for 24 hrs by MTT assay	[PMID: 36463729]
MLM	ED₅₀	>25 μM Compound: 7i	Cytotoxicity against human MLM melanoma cell line. Cytotoxicity against human MLM melanoma cell line.	[PMID: 1613753]
NCI-H460	GI₅₀	0.62 μg/mL Compound: 1b	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
NCI-H460	GI₅₀	0.62 μg/mL Compound: 4b	In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line. In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line.	[PMID: 12036362]
P388	ED₅₀	2.77 μg/mL Compound: 4b	In vitro inhibition of P388 (murine leukemia) cell proliferation. In vitro inhibition of P388 (murine leukemia) cell proliferation.	[PMID: 12036362]
SF-268	GI₅₀	0.56 μg/mL Compound: 1b	Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
SF-268	GI₅₀	5.6 μg/mL Compound: 4b	In vitro growth inhibition of central nervous system SF-268 cell line. In vitro growth inhibition of central nervous system SF-268 cell line.	[PMID: 12036362]
SK-BR-3	IC₅₀	111.8 μM Compound: TMS; 66	Anticancer activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
SK-MEL	IC₅₀	12.2 μM Compound: 3	Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
SK-MEL-5	ED₅₀	8.8 μM Compound: 7i	Compound was evaluated for cytotoxicity against human SKMEL-5 melanoma cell line. Compound was evaluated for cytotoxicity against human SKMEL-5 melanoma cell line.	[PMID: 1613753]
SK-OV-3	IC₅₀	55.5 μM Compound: 3	Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
SW480	IC₅₀	54 μM Compound: 3	Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs	[PMID: 20395019]
Vero	IC₅₀	26.7 μM Compound: 3	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]

In Vitro

Trans-Trimethoxyresveratrol exhibits significant cytotoxic potencies against several tumor cells with IC₅₀s of 0.8 g/mL (A549 cells), 1.2 μM (MDA-MB-231 cells) and 2.5 μM (LNCaP cells) ^[1].
. Trans-Trimethoxyresveratrol (1-100 μM, 24-72 h) is 30 to 100 times more potent than Resveratrol in inhibiting endothelial cell proliferation, sprouting, collagen gel invasion, and morphogenesis (ID₅₀ = 0.3-3.0 μM)^[2].
Trans-Trimethoxyresveratrol (1 μM, 3 h) significantly disrupts the microtubule network and inhibits the formation of the lumen^[2].
Trans-Trimethoxyresveratrol (1 μM, 24 h) induces apoptosis only in subconfluent endothelial cells and apoptotic regression of immature vessels in the ex vivo rat aorta ring assay^[2].
Trans-Trimethoxyresveratrol (0.1 μM, 6 h) can quickly (within 30 minutes) cause the blood flow in zebrafish embryos to stop, and the formed blood vessels can be eliminated within 6 hours^[2].
Trans-Trimethoxyresveratrol (300 pmol/implant, 48 h) inhibits blood vessel growth and causes the disappearance of pre-existing blood vessels in the area vasculosa of the chick embryo^[2].
Trans-Trimethoxyresveratrol (3-100 μM, 20 h) downregulates of VEGFR2 and induces G2/M cell-cycle arrest of zebrafish embryos^[3].
Trans-Trimethoxyresveratrol (0.5-50 μM, 48 h) reduces Gefitinib (HY-50895) resistance in H1299 and PC-9/GR cells via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498^[4].
Trans-Trimethoxyresveratrol (1-10 μM, 0-24 h) can induce the generation of ROS and DNA damage, activate the p53/PUMA/Bax pathway, and enhance the apoptosis sensitivity of 143B cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[3]

Cell Line:

zebrafish embryos
Concentration:

10 μM
Incubation Time:

20 h
Result:

Suppressed transcription of VEGFR2.

Cell Cycle Analysis^[3]

Cell Line:

zebrafish embryos
Concentration:

3, 10, 30 and 100 μM
Incubation Time:

20 h
Result:

Induced cell-cycle arrest at G2/M phase.

Western Blot Analysis^[4]

Cell Line:

H1299 and PC-9/GR cells
Concentration:

0.5, 5 and 50 μM
Incubation Time:

48 h
Result:

Decreased the Bcl-2/Bax and p-Akt/Akt while Increased PC-9/GR.

RT-PCR^[4]

Cell Line:

H1299 and PC-9/GR cells
Concentration:

5 μM
Incubation Time:

48 h
Result:

Increased the levels of miR-345 and miR-498.
Increased the Bax and caspase-3, and decreased Bcl-2.

Western Blot Analysis^[6]

Cell Line:

143B cells
Concentration:

2.5 μM
Incubation Time:

1, 2, 4, 8, 16 and 24 h
Result:

Activated caspases and increased PARP-1 cleavage.
Promoted the phosphorylation of p53, and upregulated PUMA and Bax.
Increased the level of γH2AX.

In Vivo

Trans-Trimethoxyresveratrol (30 mg/kg, p,o., once daily for 30 days) exerts anti-tumor effects in H1299 cells induced xenograft mice model^[4].
Trans-Trimethoxyresveratrol (1 mg/kg, p,o., every two days for 4 weeks) significantly inhibited tumor growth in 143B cells induced mice xenograft model^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

H1299 cells induced xenograft model established in BALB/c nude mice^[4]
Dosage:

30 mg/kg alone or with 25 mg/kg Gefitinib (HY-50895)
Administration:

Oral administration (p.o.), once daily for 30 days
Result:

The growth rates of tumour volume and weight were smaller but that the combined inhibition was more remarkable.

Animal Model:

143B cells induced xenograft model established in BALB/c nude mice^[6]
Dosage:

1 mg/kg and 0.1 mg/kg TNF-related apoptosis-inducing ligand (TRAIL)
Administration:

Oral administration (p.o.), every two days for 4 weeks
Result:

Inhibited the development ofosteosarcoma without significant toxicity.

Chemical Information

CAS No. 22255-22-7
Appearance Solid
분자량 270.32
화학식 C₁₇H₁₈O₃
Color White to off-white
SMILES

COC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C=C1
Synonyms

trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene
Structure Classification
- Stilbenes
Initial Source
- Plants
- other families
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

용액&용해도

In Vitro:

DMSO : ≥ 50 mg/mL (184.97 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6993 mL

18.4966 mL

36.9932 mL

5 mM

0.7399 mL

3.6993 mL

7.3986 mL

10 mM

0.3699 mL

1.8497 mL

3.6993 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (758 KB)
- English - EN (758 KB)
- Français - FR (758 KB)
- Deutsch - DE (758 KB)
- Norwegian - NO (758 KB)
- Español - ES (758 KB)
- Swedish - SV (758 KB)
- Italian - IT (758 KB)
- Korean - KR (758 KB)
- Portuguese - PT (758 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Aldawsari FS, Velázquez-Martínez CA. 3,4',5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency. Invest New Drugs. 2015 Jun;33(3):775-86. [Content Brief]

[2]. Belleri M,et al. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene. Mol Pharmacol. 2005 May;67(5):1451-9. [Content Brief]

[3]. Alex D, et al. Resveratrol derivative, trans-3,5,4'-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation. J Cell Biochem. 2010 Feb 1;109(2):339-46. [Content Brief]

[4]. Lu M, et al. Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498. J Cell Mol Med. 2019 Apr;23(4):2431-2441. [Content Brief]

[5]. Lin HS, Ho PC. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. J Pharm Sci. 2011 Oct;100(10):4491-500. [Content Brief]

[6]. Feng Y, et al. Resveratrol Derivative, Trans-3, 5, 4'-Trimethoxystilbene Sensitizes Osteosarcoma Cells to Apoptosis via ROS-Induced Caspases Activation. Oxid Med Cell Longev. 2021 Mar 25;2021:8840692. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6993 mL	18.4966 mL	36.9932 mL	92.4830 mL
	5 mM	0.7399 mL	3.6993 mL	7.3986 mL	18.4966 mL
	10 mM	0.3699 mL	1.8497 mL	3.6993 mL	9.2483 mL
	15 mM	0.2466 mL	1.2331 mL	2.4662 mL	6.1655 mL
	20 mM	0.1850 mL	0.9248 mL	1.8497 mL	4.6241 mL
	25 mM	0.1480 mL	0.7399 mL	1.4797 mL	3.6993 mL
	30 mM	0.1233 mL	0.6166 mL	1.2331 mL	3.0828 mL
	40 mM	0.0925 mL	0.4624 mL	0.9248 mL	2.3121 mL
	50 mM	0.0740 mL	0.3699 mL	0.7399 mL	1.8497 mL
	60 mM	0.0617 mL	0.3083 mL	0.6166 mL	1.5414 mL
	80 mM	0.0462 mL	0.2312 mL	0.4624 mL	1.1560 mL
	100 mM	0.0370 mL	0.1850 mL	0.3699 mL	0.9248 mL

Keywords

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

trans-Trimethoxyresveratrol

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Pulmonary Fibrosis Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

All VEGFR Isoforms

All Caspase Isoforms

Biological Activity

Chemical Information

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

trans-Trimethoxyresveratrol Related Classifications

HY-N1408 Related Classifications